Can Semaglutide Cause Elevated Liver Enzymes?

The decision you are probably trying to make

If you have recently had blood tests showing elevated liver enzymes, or you know you have a liver condition and are weighing up whether semaglutide is right for you, the question above is an entirely reasonable one to bring to your clinical team. It is also one our prescribers hear regularly. The honest answer is that semaglutide's relationship with the liver is not straightforward: it can raise certain enzyme markers in some individuals, it can lower them in others with fatty liver disease, and it can cause gallbladder problems that affect liver readings indirectly. Which of those applies to you depends on your baseline health, your current liver function, and any other medicines you take. No article, however thorough, can resolve that for you; only your prescriber can. What this page can do is lay out what is currently known, what remains uncertain, and what you should watch for.

You can read a fuller treatment overview on the Wegovy information page if you want to understand how semaglutide works more broadly before returning to the liver-specific detail below.

What clinical data and the MHRA tell us about semaglutide and liver enzymes

The NHS medicines page for semaglutide lists gastrointestinal effects as the most commonly reported side effects, with liver-specific abnormalities noted as uncommon but possible. In the STEP 1 phase-3 trial (published in the New England Journal of Medicine), participants taking 2.4mg semaglutide weekly for 68 weeks showed improvements in markers of metabolic dysfunction (including some liver-related parameters) compared with placebo, largely because weight loss itself reduces hepatic fat.

The picture changes with gallbladder events, which the Mounjaro and Wegovy SmPCs on the eMC list as a recognised class effect of GLP-1 medicines. Gallstones and inflammation of the gallbladder (cholecystitis) can cause secondary rises in bilirubin, ALT and AST (enzymes that would show up on a standard liver function test) even when the liver itself is not directly affected. So elevated liver enzymes while taking semaglutide are not automatically a signal of liver toxicity; they may reflect a gallbladder event that needs separate investigation.

More recently, the MHRA granted conditional approval on 3 July 2026 for semaglutide (Wegovy) to treat MASH, metabolic dysfunction-associated steatohepatitis, a form of serious fatty liver disease. That approval reflects trial evidence that semaglutide can reduce liver inflammation and fibrosis in eligible patients. This is a separate licensed indication from weight management and would only be initiated by a specialist. Our page on semaglutide and liver enzymes covers this developing area in more detail.

What remains uncertain, and why your GP's view matters

Research into semaglutide's long-term effects on the liver is still active, and guidance continues to evolve. What is not yet fully characterised is the precise rate of clinically meaningful enzyme elevation in people who do not have underlying liver or gallbladder conditions, and whether that elevation is sustained or resolves with continued treatment. Individual factors (concurrent medicines, alcohol use, pre-existing liver conditions, and genetic variation in liver enzyme metabolism) all influence how a given person's results will look. If you want a focused summary of the current evidence, our page on whether semaglutide causes liver damage brings together the key data in one place.

If your liver enzyme readings were elevated before starting semaglutide, a comparison with your baseline is essential; a rise that looks alarming in isolation may be within normal variation for you, or it may signal something that warrants a pause in treatment. Only your GP or specialist, with your full history and recent bloods in front of them, can make that call. Our clinical team at nume (sorry, at nume) reviews each patient's full clinical picture before and during treatment, but for an active concern about liver function, your GP or a hepatologist should always be your first contact.

Questions about how semaglutide interacts with other systems (including heart rate) are covered on the Wegovy and elevated heart rate page if that is also relevant to your situation.

Pregnancy, breastfeeding, and liver concerns: clear guidance

Semaglutide is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive. The Wegovy and pregnancy page sets out the full reasoning, but the short version is that animal studies raised concerns about fetal harm, human safety data are limited, and the MHRA's guidance is unambiguous: treatment should be stopped before attempting to conceive. If you are in this group and are also experiencing abnormal liver enzymes, the clinical situation is more complex still; a conversation with your GP or obstetrician (not an online pharmacy) is the right starting point.

For anyone not in those groups who is wondering whether semaglutide might be clinically appropriate for them, the free consultation with our prescribers is where that conversation begins. A GPhC-registered Independent Prescriber reads every submission personally and considers your full medical background, not just your BMI. If liver enzyme results are part of your history, bring them: they are exactly the kind of information that shapes a prescriber's decision. Older patients often ask whether the treatment is worth pursuing, and our page on whether elderly people can lose weight on semaglutide addresses that question directly. You can also explore the broader range of weight-loss treatment options if you want to compare what is available before starting a consultation.